Strensiq (asfotase alfa) prior authorization
Prior authorization and medical necessity criteria for coverage of Strensiq (asfotase alfa) for treatment of perinatal/infantile and juvenile-onset hypophosphatasia; applies to UnitedHealthcare pharmacy programs and providers submitting requests.
Updated initial and reauthorization criteria and references.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.